abstract |
The present invention provides and/or increases an immune response mediated by cellular immunotherapy, such as by adopting CD8+ central memory T cells or a combination of genetically modified CD4+ T cells and central memory T cells to express a chimeric receptor. Provided are nucleic acids, vectors, host cells, methods, and compositions comprising: In an embodiment, the genetically modified host cell comprises a polynucleotide encoding a ligand binding domain, a polynucleotide comprising a custom spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain contains nucleic acids that Surprisingly, it was found that the length of the spacer region can affect the ability of chimeric receptor degenerate T cells to recognize target cells in vitro and affect the in vivo efficacy of chimeric receptor degenerate T cells. Pharmaceutical formulations prepared by this method and methods of use thereof are also described. |